Reuters logo
6 months ago
BRIEF-Perrigo signs agreement to divest tysabri royalty stream for up to $2.85 billion
February 27, 2017 / 9:58 PM / 6 months ago

BRIEF-Perrigo signs agreement to divest tysabri royalty stream for up to $2.85 billion

Feb 27 (Reuters) - Perrigo Company Plc

* Perrigo signs agreement to divest tysabri® royalty stream for up to $2.85 billion

* Perrigo signs agreement to divest tysabri® royalty stream for up to $2.85 billion

* Perrigo company plc - deal includes up to $650 million in potential milestone payments based upon future global net sales of tysabri in 2018 and 2020

* Perrigo company plc - transaction is valued at a total consideration of up to $2.85 billion, including $2.2 billion in cash

* Perrigo company - royalty pharma will acquire all of perrigo's rights to receive tysabri(® )royalty payments from and after january 1, 2017

* Perrigo company - says royalty pharma will acquire all of perrigo's rights to receive tysabri royalty payments from and after january 1, 2017

* Perrigo company plc - perrigo will also assign to royalty pharma certain information and audit rights under perrigo's existing agreement with biogen

* Perrigo - royalty pharma to pay additional payments of $250 million if royalties earned on global sales of tysabri meet specified thresholds during 2018

* Perrigo company- royalty pharma to pay additional payments of $400 million if royalties earned on global net sales of tysabri meet specified thresholds in 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below